Skip to content
Review

Association of GLP-1 receptor agonist and SGLT2 inhibitor use with outcomes in patients with type 2 diabetes undergoing pacemaker implantation.

Nov 2026 · Current problems in cardiology · pp. 103492 · 0 citations · 38 references
Medicine

Abstract

Aims

Heart failure (HF) remains prevalent following pacemaker implantation, with patients with type 2 diabetes mellitus (T2DM) representing a particularly vulnerable population. Whether use of contemporary glucose-lowering therapies is associated with subsequent clinical outcomes has not been well characterized. We investigated the associations of sodium-glucose cotransporter 2 inhibitor (SGLT2i) and glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy, individually and in combination, with post-implantation clinical outcomes.

Methods

Electronic health records identified 3,609 patients with T2DM who underwent pacemaker implantation from 2016-2023. Based on peri-implantation medication dispensing, patients were classified as SGLT2i (n = 438), GLP-1RA (n = 193), combined therapy (n = 231), or neither (n = 2,747). Following a 90-day landmark period, three-year risks of all-cause mortality and HF hospitalization were evaluated using multinomial propensity score-based inverse probability of treatment weighting and Cox proportional hazards models.

Results

Overall, 463 patients (12.8%) died. All treatment groups showed lower all-cause mortality than controls, with the greatest reduction observed in the combination therapy group (HR 0.41; 95% CI, 0.22-0.77; P = 0.006). HF hospitalization occurred in 295 patients (8.2%), significantly reduced in combination therapy (HR 0.35; 95% CI, 0.17-0.74; P = 0.006), with trends toward benefit in monotherapy groups.

Conclusions

Among patients with T2DM undergoing permanent pacemaker implantation, SGLT2i and GLP-1RA therapy were associated with lower all-cause mortality, while combined therapy was additionally associated with fewer HF hospitalizations. These findings support further evaluation of cardiometabolic therapies after pacemaker implantation in randomized trials.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.